help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bui, T.
Right arrow Articles by Straus, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bui, T.
Right arrow Articles by Straus, D. S.
Endocrinology Vol. 138, No. 3 985-993
Copyright © 1997 by The Endocrine Society


Articles

Prostaglandin A2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells1

Tim Bui, Chiaoyun Kuo, Peter Rotwein2 and Daniel S. Straus

Biomedical Sciences Division and Biology Department, University of California (T.B., C.K., D.S.S.), Riverside, California 92521-0121; and Departments of Internal Medicine, and Biochemistry and Molecular Biophysics, Washington University School of Medicine (P.R.), St. Louis, Missouri 63110

Address all correspondence and requests for reprints to: Daniel S. Straus, Biomedical Sciences Division, University of California, Riverside, California 92521-0121. E-mail: daniel.straus{at}ucr.edu

The cyclopentenone PGs (PGA and PGJ series) inhibit tumor cell proliferation in vitro and tumorigenesis in vivo via mechanisms that are at present poorly understood. The C6 rat glioma cell line synthesizes and secretes insulin-like growth factor-I (IGF-I), which is believed to act as an autocrine factor for these cells. PGA2 inhibits the proliferation of the C6 cells and causes an increase in the fraction of cells in the G1 phase of the cell cycle. The inhibition of cell proliferation by PGA2 is accompanied by a decrease in the abundance of IGF-I messenger RNA (mRNA). This regulation of IGF-I gene expression is specific, as the abundance of hypoxanthine-guanine phosphoribosyl transferase (HPRT) and ubiquitin mRNA is not significantly affected by PGA2. The repression of IGF-I gene expression is observed at PGA2 concentrations as low as 10 µM and is evident within 4 h after treatment of the C6 cells with PGA2. In addition to specifically regulating the expression of the IGF-I gene, PGA2 also decreases the abundance of cyclin D1 mRNA and increases the abundance of Waf1 mRNA. The inhibition of cell proliferation by PGA2 is partially reversed by coaddition of IGF-I, indicating partial dominance of IGF-I action over PGA2 action. To investigate the molecular basis for the regulation of IGF-I gene expression by PGA2, we developed a sensitive RT-PCR assay for IGF-I nuclear transcripts. A similar assay was developed for quantifying HPRT transcripts, which were used as a control. Treatment of the C6 cells with 20 µM PGA2 resulted in approximately a 6-fold decrease in IGF-I mRNA and IGF-I nuclear transcripts. In contrast, HPRT mRNA and nuclear transcript levels were not significantly affected by PGA2. These results indicate that the decrease in IGF-I mRNA abundance that occurs in response to PGA2 is caused largely by a decrease in IGF-I nuclear transcript levels. To identify the cis-acting element that mediates the effect of PGA2 on IGF-I transcription, C6 cells were transiently transfected with IGF-I/luciferase expression constructs in which luciferase transcription is driven by IGF-I P1 promoter fragments extending from -1711 to +328 or from -1114 to +328 relative to the beginning of exon 1. Treatment of cells with PGA2 in these transient transfection assays did not decrease luciferase activity. These results suggest that the cis-acting regulatory element required for the response to PGA2 is located outside the -1711 to +328 promoter interval.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Granado, A. I Martin, M{a} A. Villanua, and A. Lopez-Calderon
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1656 - E1665.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
G. E. McCall, D. L. Allen, F. Haddad, and K. M. Baldwin
Transcriptional regulation of IGF-I expression in skeletal muscle
Am J Physiol Cell Physiol, October 1, 2003; 285(4): C831 - C839.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
P. A. Campo, S. Das, C.-H. Hsiang, T. Bui, C. E. Samuel, and D. S. Straus
Translational Regulation of Cyclin D1 by 15-Deoxy-{Delta}12,14-Prostaglandin J2
Cell Growth Differ., September 1, 2002; 13(9): 409 - 420.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Wang and M. L. Adamo
Cyclic Adenosine 3',5'-Monophosphate Inhibits Insulin-Like Growth Factor I Gene Expression in Rat Glioma Cell Lines: Evidence for Regulation of Transcription and Messenger Ribonucleic Acid Stability
Endocrinology, July 1, 2001; 142(7): 3041 - 3050.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
H. Hirano, M. B. S. Lopes, E. R. Laws Jr., T. Asakura, M. Goto, J. E. Carpenter, L. R. Karns, and S. R. VandenBerg
Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas
Neuro-oncol, April 1, 1999; 1(2): 109 - 119.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society